Product news

Share this article:
Eli Lilly announced that the FDA has approved Strattera (atomoxetine HCI) for maintenance treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.

Trudell Medical International announced FDA approval of Alvesco (ciclesonide) inhalation aerosol in combination with the Aerocount Dose Indicator. Alvesco, a novel inhaled corticosteroid, will be distributed in the US by Sepracor under an agreement with Nycomed based in Europe. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions